Efferent Labs at Bio International 2018

FOR IMMEDIATE RELEASE Efferent Labs™ at 2018 BIO International Convention (BUFFALO, NY) April 15, 2018 – Efferent Labs CEO Bill…

Read more

Efferent Labs at NYBio 2018

FOR IMMEDIATE RELEASE Efferent Labs™ at 2018 NewYorkBIO (BUFFALO, NY) April 24, 2016 – Efferent Labs will present the CytoComm™…

Read more

Efferent Labs Taps Evotec to Advance Implantable Biosensor for R&D, Oncology

FierceBiotech Efferent Labs has inked a deal with Evotec to develop its implantable biosensor technology. The device, which is injected…

Read more

Life-Sciences Accelerator Program Selects Efferent Labs

The Buffalo News Efferent Labs chosen to participate in Life-science accelerator program.  Click here to read the entire article

Read more

Could a Biosensor Help Personalize Cancer Treatment?

WGRZ Innovate WNY – Could a Biosensor Help Personalize Cancer Treatment? Click here to watch the video.

Read more

Raland Therapeutics is Now Efferent Labs

Rochester Democrat & Chronicle Raland Therapeutics Inc., a developer of medical technology devices, has changed its name to Efferent Labs, Inc. Click…

Read more

Implantable Sensor Would Detect Changes in Body Before Health Problems Arise

News 8 WROC Rochester Efferent Labs CMO Dr. Spencer Rosero discusses Efferent’s disruptive technology. Click here to watch the video

Read more

Making the Promise of Personalized Medicine a Reality

Businessinterviews.com Efferent Labs CEO Bill Rader speaks with Businessinterviews.com to discuss CytoComm™ and the life sciences landscape. Click here to read…

Read more

Tech bubble? Pro: Focus on disruptive companies

CNBC Efferent Chairman Carl Yankowski discusses our disruptive technology, CytoComm™, on Fast Money Half Time Report. Click here to watch…

Read more